ABVC BioPharma Inc. (NASDAQ:ABVC) saw an upside of 10.09% to close Tuesday at $2.40 after adding $0.22 on the day. The 5-day average trading volume is 342,620 shares of the company’s common stock. It has gained $2.50 in the past week. An average of 359,430 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,061,124.
ABVC’s 1-month performance is -20.00% or -$0.81 on its low of $2.11 reached on 10/08/21. The company’s shares have touched a 52-week low of $1.95 and high of $29.95, with the stock’s rally to the 52-week high happening on 05/11/21. YTD, ABVC has lost -52.94% or -$2.70. However, the current price is down -91.99%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
ABVC BioPharma Inc. (ABVC) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.ABVC stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 116.88 while the price-to-book (PB) in the most recent quarter is 40.00.
ABVC BioPharma Inc.’s quick ratio for the period ended December 30 was 0.80, with the current ratio over the same period at 0.80 meaning that ABVC stock is not able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending December 30 was 1.93, while the total debt to equity was 3.21. In terms of profitability, the gross margin trailing 12 months is 97.40%. The trailing 12-month EBITDA margin is -1753.18%. The firm’s gross profit as reported stood at $0.46 million against revenue of $0.48 million.
For the quarterly period ending December 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected ABVC to announce -$0.1 per share in earnings in its latest quarter, but it posted -$0.24, representing a -140.00% surprise. EBITDA for the quarter stood at more than -$2.03 million. ABVC stock balance sheet for the quarter ending December 30 shows that total liabilities totaled 8.43 million, with total debt at $6.5 million. Shareholders hold equity totaling $24.47 million
Let’s look briefly at ABVC BioPharma Inc. (ABVC) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 49.75% to suggest the stock is trending Neutral, with historical volatility in this time period at 62.43%.
The stock’s 5-day moving average is $2.22, reflecting a +9.09% or $0.20 change from its current price. ABVC is currently trading -20.79% above its 20-day SMA, -56.36% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -51.52% and -45.45% respectively.
Stochastic %K and %D was 12.30% and 6.28% and the average true range (ATR) pointed at 0.24. The RSI (14) points at 45.88%, while the 14-day stochastic is at 26.12% with the period’s ATR at 0.28. The stock’s 9-day MACD Oscillator is pointing at 0.01 and -0.09 on the 14-day charts.
What is ABVC’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $9.50 and a high of $9.50, with their median price target at $9.50. Looking at these predictions, the average price target given by analysts is for ABVC BioPharma Inc. (ABVC) stock is $9.50.